---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000099"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:10:06.443562+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NextCure doses first patient in Phase 1 study of B7-H4 ADC LNCB74 for multiple cancers

## Summary
- First patient dosed in Phase 1 study of LNCB74, a B7-H4-targeting ADC.
- LNCB74 is being developed as a therapeutic for treating multiple cancers.
- FDA cleared the IND for LNCB74 in December 2024.
- LNCB74 is developed in partnership with LigaChem Biosciences.
- Phase 1 aims to evaluate safety, tolerability, and preliminary anti-tumor activity.

## SEC filing metadata
- accession: 0001558370-25-000099
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837025000099/0001558370-25-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837025000099/nxtc-20250110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000099
- JSON: https://secwatch.observer/filing/0001558370-25-000099.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.